Abstract:Introduction: The detection of serum biomarkers holds potential for non-invasive methods for early cancer detection, monitoring of disease progression, and assessment of treatment responses leading to earlier interventions that may significantly improve patient outcomes. Human epidermal growth factor receptor 2 (HER2) overexpression plays a key role in the prognosis of HER2+ breast cancer (BC). While HER2 is well-established as a cell surface marker, its soluble extracellular domain (ECD) in serum has gained attention as a potential prognostic biomarker. Elevated levels of HER2 ECD (>15ng/ml) have been associated with a poor outcome. However only a small percentage of primary BC patients have levels of HER2 ECD >15ng/ml. Research has suggested that HER2 targeted therapies can influence the rate of HER2 ECD shedding. Therefore, this study aimed to explore the association between circulating HER2 ECD levels with progression-free survival (PFS) and overall survival (OS) in patients with metastatic HER2+ BC. Methods: Matched Pre and post treatment serum samples (n=25) from BC patients enrolled in TH V THL (ICORG (CTRIAL-IE) 11-10/NCT01526369) clinical trial were assessed. Human ErbB2 (HER2) ELISA Kit (Invitrogen) was used to detect levels of soluble HER2 ECD in the serum. Serum levels were stratified as Low ( 700pg/ml n=10). Patient data correlation was used to assess PFS and OS, Kaplan-Meier survival curves were constructed based on the serum levels of HER2 ECD. Significance p values were determined using log-rank (Mantel-Cox) test. Results: Levels of HER2 ECD detected (94-1730pg/ml) did not exceed 15ng/ml for any sample. There was no significant difference in HER2 ECD levels between treatment arms (TH vs. THL) for PFS (p=0.4685) or OS (p=0.1376). There was no change between the pre and post treatment HER2 ECD serum levels in the samples tested (p=0.344). However, when pre-treatment samples were stratified based on Low, Intermediate or High HER2 ECD levels, there was a significant increase in PFS for patients in the High cohort. Median PFS increased from 8.31 months in the Low cohort to 13.57 months in the Intermediate cohort. The median PFS increased further to 22.24 months in the High cohort (Log rank p=0.0197). The same parameters were applied for the analysis of OS, which also improved as the level of HER2 ECD increased. Median OS increased from 35.19 months (Low) to 68.7 months (Intermediate), with a Median OS not reached for the High cohort (Log rank p=0.077). Conclusions: Patients with HER2 ECD levels above 700pg/ml display a survival advantage in this limited study. Further validation and prospective studies are warranted to fully establish the clinical utility of HER2 ECD as a biomarker in metastatic HER2+ BC. Citation Format: Debbie O'Reilly, Marc Nolan, Ausra Teiserskiene, Bryan T. Hennessy, John Crown, Denis M. Collins. HER2 extracellular domain in serum samples from HER2+ metastatic breast cancer patients as a potential biomarker of progression-free survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7634.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

Outcome Prediction Values of Soluble Human Epidermal Growth Factor Receptor-2 Extracellular Domain in Metastatic Breast Cancer

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients

VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial

Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study

Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer

Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer

Tumour angiogenesis and c-Met pathway activation - implications in breast cancer

Vascular Emboli As A Prognostic Factor in Patients with Stage Iii Colorectal Cancer Undergoing Radical Surgery.

Prospective Validation of the Prognostic Value of Elevated Serum Vascular Endothelial Growth Factor in Patients with Nasopharyngeal Carcinoma: More Distant Metastases and Shorter Overall Survival after Treatment

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival

Abstract 7634: HER2 extracellular domain in serum samples from HER2+ metastatic breast cancer patients as a potential biomarker of progression-free survival

Association of BTN2A1+ microvesicles with overall survival and the role of γδ T cells as a potential therapeutic target in patients with hormone-sensitive metastatic prostate cancer.

VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients

Soluble CD146 cooperates with VEGF-A to generate an immunosuppressive microenvironment in CD146-positive tumors: interest of a combined antibody-based therapy